ing that the cPLA2 gene may be associated with schizophrenia. The allelic association raises the possibility that the gene for human cPLA2 may either play a role in predisposing an individual to schizophrenia or be in linkage disequilibrium with a faulty locus for schizophrenia. Several studies have directly or indirectly demonstrated that abnormal cPLA2 may be involved in schizophrenia. [5] [6] [7] The functional polymorphism of the cPLA2 gene may therefore contribute to the pathogenesis of schizophrenia.
Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy SIR -Intensive research has focused on the mechanism of Li's pharmacological actions and particularly on the phosphoinositide (PI) signal transduction cycle as the molecular substrate underlying this ion's clinical usefulness. 1 Following the demonstration that therapeutic concentrations of Li uncompetitively inhibit inositol monophosphatase (IMPase) activity, 2 it was proposed 2, 3 that this ubiquitous enzyme which regenerates intracellular free inositol is a principal therapeutic target of Li. These considerations spurred us to examine the in vitro activity of IMPase in 106 transformed lymphoblastoid cell lines derived from control subjects and bipolar disorder (BPD) patients characterized by therapeutic response to Li.
As shown in Figure 1a , cell lines from bipolar patients had significantly lower IMPase activity than cell lines from control subjects (t-test: t = 9.16, P = 0.002, d.f. = 104). When the bipolar patients were grouped according to clinical response to Li therapy (Figure 1b) , the Li responders (BP Li R) exhibited significantly lower IMPase activity compared to those patients with poor Li response (BP Li NR) (t-test: t = 3.77, P = 0.00035, d.f. = 65). Similar results were obtained if the results were analyzed by simultaneously comparing mean scores of the three (control, BP Li R and BP Li NR) subject groups (one-way ANOVA: F = 6.497, P = 0.002, d.f. 2, 93 ). Post-hoc Fisher's LSD comparison also showed that cell lines from the control group had significantly higher IMPase activity than cell lines from BP Li R (P = 0.001). BP Li R and BP Li NR cell lines also significantly differed (P = 0.046) whereas no significant post-hoc difference was observed between BP Li NR and control lines.
Considering the well-established in vitro inhibition of IMPase by therapeutic Li concentrations, 2 the results currently described appear counterintuitive. If Li is an inhibitor of IMPase, and Li is a mood-stabilizing drug, one would expect elevated IMPase levels in drug-free BPD patients. The current results suggest that the regulation of IMPase activity is more complicated and might be subject to transcriptional modulation. These considerations prompted us to examine the effect of chronic Li treatment at therapeutic concentrations on IMPase mRNA levels for the predominant brain form of this enzyme. [4] [5] [6] Five days of 1 mM Li treatment representing a minimum of two generations of growth in vitro (Figure 2) , significantly raised by 40% IMPase mRNA levels (t-test: t = 2.22, P = 0.029, d.f. = 116).
These results suggest that in BPD Li responders, who exhibit genetically determined low IMPase activity, chronic inhibition of this enzyme by Li therapy leads to transcriptional up-regulation of mRNA levels which may lead to normalized enzyme levels. A possible molecular mechanism for this Li effect is based on the presence of two adjacent consensus sequences in the 3Ј UTR of the human IMPase (IMPA) gene. 4 These two sequences are homologous to a 9-bp motif in the promoter region of some yeast genes, that represents a binding site for a regulatory factor. The factor is a complex of two proteins that together control the transcription of several phospholipid biosynthetic enzymes. 7 This complex formation is favored in the absence of inositol. Li treatment, by inhibiting IMPase, results in low inositol levels, especially in Li-responding BP patients. The drop in inositol could, as in yeast, release the suppression of transcription and thus normalize enzyme translation and activity.
The observed difference in IMPase activity within the bipolar patient group suggests genetic heterogeneity in this complex disorder. A previous preliminary study in a small group of post-mortem bipolar patient brains found no reduction in IMPase activity, but drug treatment and agonal state were not controlled. 8 Neither parametric nor non-parametric linkage investigations of the major psychoses have achieved the . Activity of IMPase was measured as previously described 2 by a laboratory worker blind to the clinical status of the subjects. Non-hospitalized bipolar patients (38 M, 39 F; average age = 43.4 ± s.d. years; range 22-80), were diagnosed according to DSM-IV criteria. Clinical response to Li was rated following careful examination of patient responses to drug therapy and withdrawal over a period of several years by a senior psychiatrist blind to the biochemical findings. Patients with insufficient clinical data to make a determination were not assigned to a response/non-response category.
Figure 2
Changes in mean (± s.e.m.) inositol monophosphatase relative (to ␤-actin, as a house-keeping gene internal standard) mRNA levels in response to 5 days in vitro 1 mM LiCl treatment in lymphoblastoid cell lines from 59 nonrelated BP and control individuals. Specific primers for amplification of this mRNA species were derived from the cDNA sequence for the IMPA chromosome 8 (8q21.13-q21.3) gene. 6 IMPase mRNA levels were determined as previously described. 10, 11 The IMPase primers (below) were designed using the computer program OLIGO based on the published cDNA structure of the human chromosome 8 IMPase.
6 IMP-UP: 5Ј TCC ATC TCA CAG TTT CAT 3Ј and IMP-LOW: 5Ј CAT CTT GCC TTC CAC ACA 3Ј. This primer pair was predicted to amplify a 205-bp fragment (222-427 bp) which was verified by comparison to a known DNA ladder marker on both agarose and acrylamide gels. The amplified DNA product was sequenced (Biological Services, Weizmann Institute, Rehovot) and was identical to the cDNA published sequence.
hoped for validation characteristic of simple Mendelian diseases. One possible solution to this conundrum is the identification of endophenotypes similar to P300 and enlarged ventricles that would allow the isolation of more homogenous diagnostic groups based on common genetic effects. Although endophenotypes may also be useful as covariates in linkage studies, the complex nature of these traits hinders their application. In fact, they may be no easier to analyze at the chromosomal level than the primary disease category. On the other hand, cellular endophenotypes are positioned much closer to genes and are considerably easier to map to specific chromosomal loci. 9 Our current results showing that low IMPase activity partially characterizes BPD patients, particularly Li responders, suggest that this measure may be one such useful cellular endophenotype.
